|
US4433059A
(en)
|
1981-09-08 |
1984-02-21 |
Ortho Diagnostic Systems Inc. |
Double antibody conjugate
|
|
US4444878A
(en)
|
1981-12-21 |
1984-04-24 |
Boston Biomedical Research Institute, Inc. |
Bispecific antibody determinants
|
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4882282A
(en)
|
1985-08-16 |
1989-11-21 |
Immunex Corporation |
DNA sequences encoding bovine interleukin-2
|
|
US6548640B1
(en)
|
1986-03-27 |
2003-04-15 |
Btg International Limited |
Altered antibodies
|
|
US5225539A
(en)
|
1986-03-27 |
1993-07-06 |
Medical Research Council |
Recombinant altered antibodies and methods of making altered antibodies
|
|
GB8607679D0
(en)
|
1986-03-27 |
1986-04-30 |
Winter G P |
Recombinant dna product
|
|
US5869620A
(en)
|
1986-09-02 |
1999-02-09 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
|
US5906936A
(en)
|
1988-05-04 |
1999-05-25 |
Yeda Research And Development Co. Ltd. |
Endowing lymphocytes with antibody specificity
|
|
JPH021556A
(ja)
|
1988-06-09 |
1990-01-05 |
Snow Brand Milk Prod Co Ltd |
ハイブリッド抗体及びその作製方法
|
|
US6303121B1
(en)
|
1992-07-30 |
2001-10-16 |
Advanced Research And Technology |
Method of using human receptor protein 4-1BB
|
|
US6905680B2
(en)
|
1988-11-23 |
2005-06-14 |
Genetics Institute, Inc. |
Methods of treating HIV infected subjects
|
|
US6534055B1
(en)
|
1988-11-23 |
2003-03-18 |
Genetics Institute, Inc. |
Methods for selectively stimulating proliferation of T cells
|
|
US6352694B1
(en)
|
1994-06-03 |
2002-03-05 |
Genetics Institute, Inc. |
Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
|
|
US5858358A
(en)
|
1992-04-07 |
1999-01-12 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for selectively stimulating proliferation of T cells
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5399346A
(en)
|
1989-06-14 |
1995-03-21 |
The United States Of America As Represented By The Department Of Health And Human Services |
Gene therapy
|
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
|
US5585362A
(en)
|
1989-08-22 |
1996-12-17 |
The Regents Of The University Of Michigan |
Adenovirus vectors for gene therapy
|
|
AU6290090A
(en)
|
1989-08-29 |
1991-04-08 |
University Of Southampton |
Bi-or trispecific (fab)3 or (fab)4 conjugates
|
|
GB8928874D0
(en)
|
1989-12-21 |
1990-02-28 |
Celltech Ltd |
Humanised antibodies
|
|
US5273743A
(en)
|
1990-03-09 |
1993-12-28 |
Hybritech Incorporated |
Trifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
|
|
GB9012995D0
(en)
|
1990-06-11 |
1990-08-01 |
Celltech Ltd |
Multivalent antigen-binding proteins
|
|
US5582996A
(en)
|
1990-12-04 |
1996-12-10 |
The Wistar Institute Of Anatomy & Biology |
Bifunctional antibodies and method of preparing same
|
|
US6319494B1
(en)
|
1990-12-14 |
2001-11-20 |
Cell Genesys, Inc. |
Chimeric chains for receptor-associated signal transduction pathways
|
|
DE69123241T2
(de)
|
1990-12-14 |
1997-04-17 |
Cell Genesys Inc |
Chimärische ketten zur transduktion von rezeptorverbundenen signalwegen
|
|
US7049136B2
(en)
|
1991-03-07 |
2006-05-23 |
The General Hospital Corporation |
Redirection of cellular immunity by receptor chimeras
|
|
IL101147A
(en)
|
1991-03-07 |
2004-06-20 |
Gen Hospital Corp |
Redirection of cellular immunity by receptor chimeras
|
|
US6004811A
(en)
|
1991-03-07 |
1999-12-21 |
The Massachussetts General Hospital |
Redirection of cellular immunity by protein tyrosine kinase chimeras
|
|
DE69233482T2
(de)
|
1991-05-17 |
2006-01-12 |
Merck & Co., Inc. |
Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
|
|
DE4118120A1
(de)
|
1991-06-03 |
1992-12-10 |
Behringwerke Ag |
Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
|
|
US5199942A
(en)
|
1991-06-07 |
1993-04-06 |
Immunex Corporation |
Method for improving autologous transplantation
|
|
US6511663B1
(en)
|
1991-06-11 |
2003-01-28 |
Celltech R&D Limited |
Tri- and tetra-valent monospecific antigen-binding proteins
|
|
EP0940468A1
(en)
|
1991-06-14 |
1999-09-08 |
Genentech, Inc. |
Humanized antibody variable domain
|
|
US5637481A
(en)
|
1993-02-01 |
1997-06-10 |
Bristol-Myers Squibb Company |
Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
|
|
ES2136092T3
(es)
|
1991-09-23 |
1999-11-16 |
Medical Res Council |
Procedimientos para la produccion de anticuerpos humanizados.
|
|
US5932448A
(en)
|
1991-11-29 |
1999-08-03 |
Protein Design Labs., Inc. |
Bispecific antibody heterodimers
|
|
EP1291360A1
(en)
|
1991-12-13 |
2003-03-12 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
JP3490437B2
(ja)
|
1992-01-23 |
2004-01-26 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング |
単量体および二量体抗体フラグメント融合タンパク質
|
|
DE69333807T2
(de)
|
1992-02-06 |
2006-02-02 |
Chiron Corp., Emeryville |
Marker für krebs und biosynthetisches bindeprotein dafür
|
|
GB9203459D0
(en)
|
1992-02-19 |
1992-04-08 |
Scotgen Ltd |
Antibodies with germ-line variable regions
|
|
US8211422B2
(en)
|
1992-03-18 |
2012-07-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric receptor genes and cells transformed therewith
|
|
IL104570A0
(en)
|
1992-03-18 |
1993-05-13 |
Yeda Res & Dev |
Chimeric genes and cells transformed therewith
|
|
DE69318016D1
(de)
|
1992-05-08 |
1998-05-20 |
Creative Biomolecules Inc |
Mehrwertige Chimäre Proteine Anologe und Verfahren zu deren Anwendungen
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
US5350674A
(en)
|
1992-09-04 |
1994-09-27 |
Becton, Dickinson And Company |
Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
|
|
US5639641A
(en)
|
1992-09-09 |
1997-06-17 |
Immunogen Inc. |
Resurfacing of rodent antibodies
|
|
CA2145278C
(en)
|
1992-09-25 |
2009-03-10 |
Commonwealth Scientific And Industrial Research Organisation |
Target binding polypeptide
|
|
GB9221657D0
(en)
|
1992-10-15 |
1992-11-25 |
Scotgen Ltd |
Recombinant bispecific antibodies
|
|
US5837821A
(en)
|
1992-11-04 |
1998-11-17 |
City Of Hope |
Antibody construct
|
|
GB9323648D0
(en)
|
1992-11-23 |
1994-01-05 |
Zeneca Ltd |
Proteins
|
|
DK0672142T3
(da)
|
1992-12-04 |
2001-06-18 |
Medical Res Council |
Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
|
|
US7211259B1
(en)
|
1993-05-07 |
2007-05-01 |
Immunex Corporation |
4-1BB polypeptides and DNA encoding 4-1BB polypeptides
|
|
US6476198B1
(en)
|
1993-07-13 |
2002-11-05 |
The Scripps Research Institute |
Multispecific and multivalent antigen-binding polypeptide molecules
|
|
US5635602A
(en)
|
1993-08-13 |
1997-06-03 |
The Regents Of The University Of California |
Design and synthesis of bispecific DNA-antibody conjugates
|
|
WO1995007984A1
(en)
|
1993-09-16 |
1995-03-23 |
Indiana University Foundation |
Human receptor h4-1bb
|
|
WO1995009917A1
(en)
|
1993-10-07 |
1995-04-13 |
The Regents Of The University Of California |
Genetically engineered bispecific tetravalent antibodies
|
|
SE9400088D0
(sv)
|
1994-01-14 |
1994-01-14 |
Kabi Pharmacia Ab |
Bacterial receptor structures
|
|
CA2188422C
(en)
|
1994-05-02 |
2011-03-15 |
Bernd Groner |
Bifunctional protein, preparation and use
|
|
US7175843B2
(en)
|
1994-06-03 |
2007-02-13 |
Genetics Institute, Llc |
Methods for selectively stimulating proliferation of T cells
|
|
US5786464C1
(en)
|
1994-09-19 |
2012-04-24 |
Gen Hospital Corp |
Overexpression of mammalian and viral proteins
|
|
WO1996013583A2
(en)
|
1994-10-20 |
1996-05-09 |
Morphosys Gesellschaft Für Proteinoptimierung Mbh |
Targeted hetero-association of recombinant proteins to multi-functional complexes
|
|
US5712149A
(en)
|
1995-02-03 |
1998-01-27 |
Cell Genesys, Inc. |
Chimeric receptor molecules for delivery of co-stimulatory signals
|
|
US6103521A
(en)
|
1995-02-06 |
2000-08-15 |
Cell Genesys, Inc. |
Multispecific chimeric receptors
|
|
ATE297986T1
(de)
|
1995-02-24 |
2005-07-15 |
Gen Hospital Corp |
Neuorientierung der zellulären immunität durch rezeptorchimären
|
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
|
US7067318B2
(en)
|
1995-06-07 |
2006-06-27 |
The Regents Of The University Of Michigan |
Methods for transfecting T cells
|
|
US6692964B1
(en)
|
1995-05-04 |
2004-02-17 |
The United States Of America As Represented By The Secretary Of The Navy |
Methods for transfecting T cells
|
|
DE69633175T2
(de)
|
1995-05-23 |
2005-08-11 |
Morphosys Ag |
Multimere proteine
|
|
US5989830A
(en)
|
1995-10-16 |
1999-11-23 |
Unilever Patent Holdings Bv |
Bifunctional or bivalent antibody fragment analogue
|
|
GB9526131D0
(en)
|
1995-12-21 |
1996-02-21 |
Celltech Therapeutics Ltd |
Recombinant chimeric receptors
|
|
CA2244363C
(en)
|
1996-02-28 |
2006-11-14 |
Ariad Gene Therapeutics, Inc. |
Synthetic derivatives of rapamycin as multimerizing agents for chimeric proteins with immunophilin-derived domains
|
|
US5874240A
(en)
|
1996-03-15 |
1999-02-23 |
Human Genome Sciences, Inc. |
Human 4-1BB receptor splicing variant
|
|
US6239259B1
(en)
|
1996-04-04 |
2001-05-29 |
Unilever Patent Holdings B.V. |
Multivalent and multispecific antigen-binding protein
|
|
WO1998006842A1
(en)
|
1996-08-16 |
1998-02-19 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
|
US6114148C1
(en)
|
1996-09-20 |
2012-05-01 |
Gen Hospital Corp |
High level expression of proteins
|
|
CA2269738A1
(en)
|
1996-10-25 |
1998-05-07 |
Mitchell H. Finer |
Targeted cytolysis of cancer cells
|
|
JP2002505574A
(ja)
|
1997-04-30 |
2002-02-19 |
エンゾン，インコーポレイテッド |
ポリアルキレンオキシド修飾された単鎖ポリペプチド
|
|
US20020062010A1
(en)
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
US20030207346A1
(en)
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
|
ATE282092T1
(de)
|
1997-06-11 |
2004-11-15 |
Borean Pharma As |
Trimerisierendes modul
|
|
WO1998056915A2
(en)
|
1997-06-12 |
1998-12-17 |
Research Corporation Technologies, Inc. |
Artificial antibody polypeptides
|
|
GB9713473D0
(en)
|
1997-06-25 |
1997-09-03 |
Celltech Therapeutics Ltd |
Biological products
|
|
US20030060444A1
(en)
|
1997-06-25 |
2003-03-27 |
Celltech Therapeutics, Ltd. |
Cell activation process and reagents therefor
|
|
EP1017716A4
(en)
|
1997-09-19 |
2001-01-03 |
Gen Hospital Corp |
Car receptors and related molecules and methods
|
|
WO1999020758A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
|
EP1027439B1
(en)
|
1997-10-27 |
2010-03-17 |
Bac Ip B.V. |
Multivalent antigen-binding proteins
|
|
WO1999021581A1
(en)
|
1997-10-28 |
1999-05-06 |
Steeves John D |
Immunological compositions and methods of use to transiently alter mammalian central nervous system myelin to promote neuronal regeneration
|
|
DK1049787T3
(da)
|
1998-01-23 |
2005-04-04 |
Vlaams Interuniv Inst Biotech |
Antistofderivater med flere anvendelsesmuligheder
|
|
CA2319236A1
(en)
|
1998-02-09 |
1999-08-12 |
Genentech, Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
|
US20040040047A1
(en)
|
1998-03-30 |
2004-02-26 |
Spencer David M. |
Regulated apoptosis using chemically induced dimerization of apoptosis factors
|
|
CZ121599A3
(cs)
|
1998-04-09 |
1999-10-13 |
Aventis Pharma Deutschland Gmbh |
Jednořetězcová molekula vázající několik antigenů, způsob její přípravy a léčivo obsahující tuto molekulu
|
|
JP4843138B2
(ja)
|
1998-04-15 |
2011-12-21 |
ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド |
Ｔ細胞阻害性受容体組成物およびその使用
|
|
DE19819846B4
(de)
|
1998-05-05 |
2016-11-24 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Multivalente Antikörper-Konstrukte
|
|
GB9809658D0
(en)
|
1998-05-06 |
1998-07-01 |
Celltech Therapeutics Ltd |
Biological products
|
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
|
AU5728999A
(en)
|
1998-07-28 |
2000-02-21 |
Micromet Ag |
Heterominibodies
|
|
JP2002524081A
(ja)
|
1998-09-04 |
2002-08-06 |
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ |
前立腺−特異的膜抗原に特異的な融合受容体およびその使用
|
|
WO2000023573A2
(en)
|
1998-10-20 |
2000-04-27 |
City Of Hope |
Cd20-specific redirected t cells and their use in cellular immunotherapy of cd20+ malignancies
|
|
US6333396B1
(en)
|
1998-10-20 |
2001-12-25 |
Enzon, Inc. |
Method for targeted delivery of nucleic acids
|
|
US6818418B1
(en)
|
1998-12-10 |
2004-11-16 |
Compound Therapeutics, Inc. |
Protein scaffolds for antibody mimics and other binding proteins
|
|
EP1171596A1
(en)
|
1999-04-16 |
2002-01-16 |
Celltech Therapeutics Limited |
Synthetic transmembrane components
|
|
US7534866B2
(en)
|
2005-10-19 |
2009-05-19 |
Ibc Pharmaceuticals, Inc. |
Methods and compositions for generating bioactive assemblies of increased complexity and uses
|
|
US7527787B2
(en)
|
2005-10-19 |
2009-05-05 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
|
CA2378179A1
(en)
|
1999-07-12 |
2001-01-18 |
Genentech, Inc. |
Promotion or inhibition of angiogenesis and cardiovascularization by tumor necrosis factor ligand/receptor homologs
|
|
WO2001029058A1
(en)
|
1999-10-15 |
2001-04-26 |
University Of Massachusetts |
Rna interference pathway genes as tools for targeted genetic interference
|
|
GB9925848D0
(en)
|
1999-11-01 |
1999-12-29 |
Celltech Therapeutics Ltd |
Biological products
|
|
US6326193B1
(en)
|
1999-11-05 |
2001-12-04 |
Cambria Biosciences, Llc |
Insect control agent
|
|
WO2001034843A1
(en)
|
1999-11-10 |
2001-05-17 |
The Uab Research Foundation |
Lentiviral vector transduction of hematopoietic stem cells
|
|
US7572631B2
(en)
|
2000-02-24 |
2009-08-11 |
Invitrogen Corporation |
Activation and expansion of T cells
|
|
AU4328801A
(en)
|
2000-02-24 |
2001-09-03 |
Xcyte Therapies Inc |
Simultaneous stimulation and concentration of cells
|
|
US6797514B2
(en)
|
2000-02-24 |
2004-09-28 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
US6867041B2
(en)
|
2000-02-24 |
2005-03-15 |
Xcyte Therapies, Inc. |
Simultaneous stimulation and concentration of cells
|
|
ES2637801T3
(es)
|
2000-04-11 |
2017-10-17 |
Genentech, Inc. |
Anticuerpos multivalentes y usos de los mismos
|
|
JP2004511430A
(ja)
|
2000-05-24 |
2004-04-15 |
イムクローン システムズ インコーポレイティド |
二重特異性免疫グロブリン様抗原結合蛋白および製造方法
|
|
IL136511A0
(en)
|
2000-06-01 |
2001-06-14 |
Gavish Galilee Bio Appl Ltd |
Genetically engineered mhc molecules
|
|
AU2001275474A1
(en)
|
2000-06-12 |
2001-12-24 |
Akkadix Corporation |
Materials and methods for the control of nematodes
|
|
AU2001270609A1
(en)
|
2000-06-30 |
2002-01-14 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw |
Heterodimeric fusion proteins
|
|
ATE545703T1
(de)
|
2000-07-25 |
2012-03-15 |
Immunomedics Inc |
Multivalentes zielbindendes protein
|
|
GB0025307D0
(en)
|
2000-10-16 |
2000-11-29 |
Celltech Chiroscience Ltd |
Biological products
|
|
US20040242847A1
(en)
|
2000-10-20 |
2004-12-02 |
Naoshi Fukushima |
Degraded agonist antibody
|
|
CA2425862C
(en)
|
2000-11-07 |
2013-01-22 |
City Of Hope |
Cd19-specific redirected immune cells
|
|
US7829084B2
(en)
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
|
AU2002247826A1
(en)
|
2001-03-13 |
2002-09-24 |
University College London |
Specific binding members
|
|
US7070995B2
(en)
|
2001-04-11 |
2006-07-04 |
City Of Hope |
CE7-specific redirected immune cells
|
|
CN1294148C
(zh)
|
2001-04-11 |
2007-01-10 |
中国科学院遗传与发育生物学研究所 |
环状单链三特异抗体
|
|
US20040175756A1
(en)
|
2001-04-26 |
2004-09-09 |
Avidia Research Institute |
Methods for using combinatorial libraries of monomer domains
|
|
US20050048512A1
(en)
|
2001-04-26 |
2005-03-03 |
Avidia Research Institute |
Combinatorial libraries of monomer domains
|
|
US20050053973A1
(en)
|
2001-04-26 |
2005-03-10 |
Avidia Research Institute |
Novel proteins with targeted binding
|
|
US7514537B2
(en)
|
2001-04-30 |
2009-04-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human gliomas
|
|
US20090257994A1
(en)
|
2001-04-30 |
2009-10-15 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
WO2002088334A1
(en)
|
2001-04-30 |
2002-11-07 |
City Of Hope |
Chimeric immunoreceptor useful in treating human cancers
|
|
CA2447851C
(en)
|
2001-06-28 |
2012-08-28 |
Domantis Limited |
Dual-specific ligand and its use
|
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
|
DE60124912T2
(de)
|
2001-09-14 |
2007-06-14 |
Affimed Therapeutics Ag |
Multimerische, einzelkettige, Tandem-Fv-Antikörper
|
|
US20030148982A1
(en)
|
2001-11-13 |
2003-08-07 |
Brenner Malcolm K. |
Bi-spcific chimeric T cells
|
|
US20030211078A1
(en)
|
2001-12-07 |
2003-11-13 |
Heavner George A. |
Pseudo-antibody constructs
|
|
US7745140B2
(en)
|
2002-01-03 |
2010-06-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
|
|
US7638325B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
US7638326B2
(en)
|
2002-01-03 |
2009-12-29 |
The Trustees Of The University Of Pennsylvania |
Activation and expansion of T-cells using an engineered multivalent signaling platform
|
|
JP4547911B2
(ja)
|
2002-02-01 |
2010-09-22 |
アリアド・ファーマシューティカルズ・インコーポレイテッド |
リン含有化合物およびその用途
|
|
CA2478011C
(en)
|
2002-03-01 |
2013-05-21 |
Immunomedics, Inc. |
Bispecific antibody point mutations for enhancing rate of clearance
|
|
JP4386741B2
(ja)
|
2002-04-15 |
2009-12-16 |
中外製薬株式会社 |
ｓｃＤｂライブラリーの作成方法
|
|
GB0210121D0
(en)
*
|
2002-05-02 |
2002-06-12 |
Celltech R&D Ltd |
Biological products
|
|
US7446190B2
(en)
|
2002-05-28 |
2008-11-04 |
Sloan-Kettering Institute For Cancer Research |
Nucleic acids encoding chimeric T cell receptors
|
|
EP1517921B1
(en)
|
2002-06-28 |
2006-06-07 |
Domantis Limited |
Dual specific ligands with increased serum half-life
|
|
GB0230203D0
(en)
|
2002-12-27 |
2003-02-05 |
Domantis Ltd |
Fc fusion
|
|
US20050129671A1
(en)
|
2003-03-11 |
2005-06-16 |
City Of Hope |
Mammalian antigen-presenting T cells and bi-specific T cells
|
|
GB0305702D0
(en)
|
2003-03-12 |
2003-04-16 |
Univ Birmingham |
Bispecific antibodies
|
|
JP2006526408A
(ja)
|
2003-04-22 |
2006-11-24 |
アイビーシー、ファーマシューティカルズ |
多価タンパク質複合体
|
|
WO2005000901A2
(en)
|
2003-05-09 |
2005-01-06 |
Duke University |
Cd20-specific antibodies and methods of employing same
|
|
US7402431B2
(en)
|
2004-03-01 |
2008-07-22 |
Immunovative Therapies, Ltd. |
T-cell therapy formulation
|
|
RU2369636C2
(ru)
|
2003-05-23 |
2009-10-10 |
Уайт |
Лиганд gitr и связанные с лигандом gitr молекулы и антитела и варианты их применения
|
|
US20050163782A1
(en)
|
2003-06-27 |
2005-07-28 |
Biogen Idec Ma Inc. |
Modified binding molecules comprising connecting peptides
|
|
US20050100543A1
(en)
|
2003-07-01 |
2005-05-12 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
|
US20050048054A1
(en)
|
2003-07-11 |
2005-03-03 |
Shino Hanabuchi |
Lymphocytes; methods
|
|
US7696322B2
(en)
|
2003-07-28 |
2010-04-13 |
Catalent Pharma Solutions, Inc. |
Fusion antibodies
|
|
EP1660186B1
(en)
|
2003-08-18 |
2013-12-25 |
MedImmune, LLC |
Humanization of antibodies
|
|
WO2005035575A2
(en)
|
2003-08-22 |
2005-04-21 |
Medimmune, Inc. |
Humanization of antibodies
|
|
WO2005019429A2
(en)
|
2003-08-22 |
2005-03-03 |
Potentia Pharmaceuticals, Inc. |
Compositions and methods for enhancing phagocytosis or phagocyte activity
|
|
US20080241884A1
(en)
|
2003-10-08 |
2008-10-02 |
Kenya Shitara |
Fused Protein Composition
|
|
US20050113564A1
(en)
|
2003-11-05 |
2005-05-26 |
St. Jude Children's Research Hospital |
Chimeric receptors with 4-1BB stimulatory signaling domain
|
|
US7435596B2
(en)
|
2004-11-04 |
2008-10-14 |
St. Jude Children's Research Hospital, Inc. |
Modified cell line and method for expansion of NK cell
|
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
|
CA2550996A1
(en)
|
2003-12-22 |
2005-07-14 |
Centocor, Inc. |
Methods for generating multimeric molecules
|
|
GB0329825D0
(en)
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
|
US20050266425A1
(en)
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
|
US8383575B2
(en)
|
2004-01-30 |
2013-02-26 |
Paul Scherrer Institut |
(DI)barnase-barstar complexes
|
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
|
WO2005118788A2
(en)
|
2004-05-27 |
2005-12-15 |
The Trustees Of The University Of Pennsylvania |
Novel artificial antigen presenting cells and uses therefor
|
|
EP1765402A2
(en)
|
2004-06-04 |
2007-03-28 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
|
US20060008844A1
(en)
|
2004-06-17 |
2006-01-12 |
Avidia Research Institute |
c-Met kinase binding proteins
|
|
JP2008512352A
(ja)
|
2004-07-17 |
2008-04-24 |
イムクローン システムズ インコーポレイティド |
新規な四価の二重特異性抗体
|
|
AU2005282700A1
(en)
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
|
WO2006036445A2
(en)
|
2004-09-24 |
2006-04-06 |
Trustees Of Dartmouth College |
Chimeric nk receptor and methods for treating cancer
|
|
US7462697B2
(en)
|
2004-11-08 |
2008-12-09 |
Epitomics, Inc. |
Methods for antibody engineering
|
|
WO2006060878A1
(en)
|
2004-12-10 |
2006-06-15 |
Peter Maccallum Cancer Institute |
Methods and compositions for adoptive immunotherapy
|
|
WO2006105021A2
(en)
|
2005-03-25 |
2006-10-05 |
Tolerrx, Inc. |
Gitr binding molecules and uses therefor
|
|
TWI671403B
(zh)
|
2005-03-31 |
2019-09-11 |
中外製藥股份有限公司 |
控制組裝之多肽的製造方法
|
|
EP1874824A4
(en)
|
2005-04-06 |
2009-12-30 |
Ibc Pharmaceuticals Inc |
METHODS OF GENERATING STABLE COMPOUND RELATED COMPLEXES OF HOMODIMERS, HOMOTRATEERS OR DIMER SIZES AND USES THEREOF
|
|
EP3479844B1
(en)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Covalent diabodies and uses thereof
|
|
ES2720160T3
(es)
|
2005-05-09 |
2019-07-18 |
Ono Pharmaceutical Co |
Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas
|
|
EP3263581B2
(en)
|
2005-05-17 |
2025-07-09 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
|
US20060263367A1
(en)
|
2005-05-23 |
2006-11-23 |
Fey Georg H |
Bispecific antibody devoid of Fc region and method of treatment using same
|
|
US20070036773A1
(en)
|
2005-08-09 |
2007-02-15 |
City Of Hope |
Generation and application of universal T cells for B-ALL
|
|
EP2500352A1
(en)
|
2005-08-19 |
2012-09-19 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
|
ATE452913T1
(de)
|
2005-08-26 |
2010-01-15 |
Pls Design Gmbh |
Bivalente igy antikörperkonstrukte für diagnostische und therapeutische anwendungen
|
|
WO2007044887A2
(en)
|
2005-10-11 |
2007-04-19 |
Transtarget, Inc. |
Method for producing a population of homogenous tetravalent bispecific antibodies
|
|
US8623356B2
(en)
|
2005-11-29 |
2014-01-07 |
The University Of Sydney |
Demibodies: dimerization-activated therapeutic agents
|
|
EP2251034B1
(en)
|
2005-12-02 |
2018-02-14 |
Icahn School of Medicine at Mount Sinai |
Chimeric newcastle disease viruses presenting non-native surface proteins and uses thereof
|
|
MX357691B
(es)
|
2006-01-13 |
2018-07-19 |
The Government Of The United States As Represented By The Secretary Of The Department Of Health And |
Il-15 y il-15r-alfa mejoradas para expresion en celulas mamiferas.
|
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
|
WO2007095338A2
(en)
|
2006-02-15 |
2007-08-23 |
Imclone Systems Incorporated |
Functional antibodies
|
|
GEP20135917B
(en)
|
2006-03-17 |
2013-09-10 |
Biogen Idec Inc |
Stabilized polypeptide compositions
|
|
ES2395969T3
(es)
|
2006-03-24 |
2013-02-18 |
Merck Patent Gmbh |
Dominios de proteínas heterodiméricas genéticamente modificados
|
|
US8946391B2
(en)
|
2006-03-24 |
2015-02-03 |
The Regents Of The University Of California |
Construction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
|
|
WO2007114325A1
(ja)
|
2006-03-31 |
2007-10-11 |
Chugai Seiyaku Kabushiki Kaisha |
二重特異性抗体を精製するための抗体改変方法
|
|
EP2799449A1
(en)
|
2006-05-25 |
2014-11-05 |
Bayer Intellectual Property GmbH |
Dimeric molecular complexes
|
|
US20070274985A1
(en)
|
2006-05-26 |
2007-11-29 |
Stefan Dubel |
Antibody
|
|
EP2418223A3
(en)
|
2006-06-12 |
2013-01-16 |
Emergent Product Development Seattle, LLC |
Single-chain multivalent binding proteins with effector function
|
|
US8497246B2
(en)
|
2006-08-18 |
2013-07-30 |
Armagen Technologies, Inc. |
Methods for diagnosing and treating CNS disorders by trans-blood-brain barrier delivery of protein compositions
|
|
EP2059533B1
(en)
|
2006-08-30 |
2012-11-14 |
Genentech, Inc. |
Multispecific antibodies
|
|
EA018573B1
(ru)
|
2006-09-22 |
2013-09-30 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
|
WO2008045437A2
(en)
|
2006-10-09 |
2008-04-17 |
The General Hospital Corporation |
Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
|
|
EP1916259A1
(en)
|
2006-10-26 |
2008-04-30 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Anti-glycoprotein VI SCFV fragment for treatment of thrombosis
|
|
DK2343286T3
(en)
|
2006-10-28 |
2015-04-13 |
Methylgene Inc |
Dibenzo [b, f] [1,4] oxazepine derivatives as inhibitors of histone deacetylase
|
|
NZ576445A
(en)
|
2006-11-02 |
2012-03-30 |
Daniel J Capon |
Hybrid immunoglobulins with moving parts
|
|
US20080131415A1
(en)
|
2006-11-30 |
2008-06-05 |
Riddell Stanley R |
Adoptive transfer of cd8 + t cell clones derived from central memory cells
|
|
US20100178684A1
(en)
|
2006-12-21 |
2010-07-15 |
Woo Savio L C |
Transgenic oncolytic viruses and uses thereof
|
|
CA2584494A1
(en)
|
2007-03-27 |
2008-09-27 |
Jeffrey A. Medin |
Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
|
|
EP2139924B1
(en)
|
2007-03-29 |
2016-07-06 |
Genmab A/S |
Bispecific antibodies and methods for production thereof
|
|
DK2141997T3
(da)
|
2007-03-30 |
2013-02-11 |
Sloan Kettering Inst Cancer |
Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
|
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
|
EP2164871A2
(en)
|
2007-06-12 |
2010-03-24 |
Wyeth a Corporation of the State of Delaware |
Anti-cd20 therapeutic compositions and methods
|
|
AU2008269032B2
(en)
|
2007-06-27 |
2013-12-05 |
Novartis Ag |
Complexes of IL-15 and IL-15Ralpha and uses thereof
|
|
CA2693677C
(en)
|
2007-07-12 |
2018-02-13 |
Tolerx, Inc. |
Combination therapies employing gitr binding molecules
|
|
WO2009018386A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
|
CA2696263C
(en)
|
2007-08-15 |
2017-06-13 |
Bing Liu |
Monospecific and multispecific antibodies and method of use
|
|
CA2703947C
(en)
|
2007-10-26 |
2018-12-04 |
Governing Council Of The University Of Toronto |
Therapeutic and diagnostic methods using tim-3
|
|
CN101970490A
(zh)
|
2007-11-27 |
2011-02-09 |
埃博灵克斯股份有限公司 |
针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
|
|
EP2641919A3
(en)
|
2007-11-30 |
2014-05-07 |
Glaxo Group Limited |
Antigen-binding constructs
|
|
US8242247B2
(en)
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
|
US8227577B2
(en)
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
|
SI2235064T1
(sl)
|
2008-01-07 |
2016-04-29 |
Amgen Inc. |
Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
|
|
WO2009091826A2
(en)
|
2008-01-14 |
2009-07-23 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
|
|
WO2009097140A1
(en)
|
2008-01-30 |
2009-08-06 |
Memorial Sloan-Kettering Cancer Center |
Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
|
|
US8379824B2
(en)
|
2008-03-06 |
2013-02-19 |
At&T Intellectual Property I, Lp |
Methods and apparatus to provide a network-based caller identification service in a voice over internet protocol network
|
|
MY163544A
(en)
|
2008-03-25 |
2017-09-29 |
Roche Glycart Ag |
Use of a type ii anti-cd20 antibody with increased antibody dependent cellular cytotoxicity (adcc) in combination with cyclophosphamide, vincristine and doxorubicine for treating non-hodgkin's lymphomas
|
|
US8591889B2
(en)
*
|
2008-04-04 |
2013-11-26 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Human monoclonal antibodies specific for CD22
|
|
WO2010003118A1
(en)
|
2008-07-02 |
2010-01-07 |
Trubion Pharmaceuticals, Inc. |
Tgf-b antagonist multi-target binding proteins
|
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
|
EP4032552B1
(en)
|
2008-08-26 |
2023-10-04 |
City of Hope |
Method and compositions for enhanced anti-tumor effector functioning of t cells
|
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性ｇｉｔｒリガンド発現細胞
|
|
CN102209729B
(zh)
|
2008-11-07 |
2016-05-25 |
安进研发（慕尼黑）股份有限公司 |
小儿急性淋巴细胞白血病的治疗方法
|
|
WO2010085660A2
(en)
|
2009-01-23 |
2010-07-29 |
Roger Williams Hospital |
Viral vectors encoding multiple highly homologous non-viral polypeptides and the use of same
|
|
SG172855A1
(en)
|
2009-01-29 |
2011-08-29 |
Abbott Lab |
Il-1 binding proteins
|
|
ES2550179T3
(es)
|
2009-02-05 |
2015-11-05 |
Icahn School Of Medicine At Mount Sinai |
Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
|
|
SG173654A1
(en)
|
2009-02-23 |
2011-09-29 |
Glenmark Pharmaceuticals Sa |
Humanized antibodies that bind to cd19 and their uses
|
|
CN102459346B
(zh)
|
2009-04-27 |
2016-10-26 |
昂考梅德药品有限公司 |
制造异源多聚体分子的方法
|
|
NZ714757A
(en)
|
2009-08-14 |
2018-07-27 |
Us Gov Health & Human Services |
Use of il-15 to increase thymic output and to treat lymphopenia
|
|
RU2595409C2
(ru)
|
2009-09-03 |
2016-08-27 |
Мерк Шарп И Доум Корп., |
Анти-gitr-антитела
|
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−２キメラ抗原受容体及び癌の治療のためのその使用
|
|
WO2011059836A2
(en)
|
2009-10-29 |
2011-05-19 |
Trustees Of Dartmouth College |
T cell receptor-deficient t cell compositions
|
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
|
ES2717629T3
(es)
|
2009-11-03 |
2019-06-24 |
Hope City |
Receptor del factor de crecimiento epidérmico truncado (EGFRt) para selección de células T transducidas
|
|
SG181952A1
(en)
|
2009-12-29 |
2012-07-30 |
Emergent Product Dev Seattle |
Heterodimer binding proteins and uses thereof
|
|
WO2011097477A1
(en)
|
2010-02-04 |
2011-08-11 |
The Trustees Of The University Of Pennsylvania |
Icos critically regulates the expansion and function of inflammatory human th17 cells
|
|
PL2560993T3
(pl)
|
2010-04-20 |
2024-11-04 |
Genmab A/S |
Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
|
|
US9089520B2
(en)
|
2010-05-21 |
2015-07-28 |
Baylor College Of Medicine |
Methods for inducing selective apoptosis
|
|
WO2011159847A2
(en)
|
2010-06-15 |
2011-12-22 |
The Regents Of The University Of California |
Receptor tyrosine kinase-like orphan receptor 1 (ror1) single chain fv antibody fragment conjugates and methods of use thereof
|
|
AU2011319727B2
(en)
|
2010-10-27 |
2016-06-30 |
Baylor College Of Medicine |
Chimeric CD27 receptors for redirecting T cells to CD70-positive malignancies
|
|
PH12013501201A1
(en)
*
|
2010-12-09 |
2013-07-29 |
Univ Pennsylvania |
Use of chimeric antigen receptor-modified t cells to treat cancer
|
|
WO2012082841A2
(en)
|
2010-12-14 |
2012-06-21 |
University Of Maryland, Baltimore |
Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer
|
|
BR112013018311A2
(pt)
|
2011-01-18 |
2017-03-21 |
Univ Pennsylvania |
sequência de ácido nucleico isolada, receptor de antígeno quimérico isolado, célula t geneticamente modificada, vetor, e, uso de uma célula t geneticamente modificada.
|
|
WO2012127464A2
(en)
|
2011-03-23 |
2012-09-27 |
Gavish-Galilee Bio Applications Ltd |
Constitutively activated t cells for use in adoptive cell therapy
|
|
RU2688185C2
(ru)
|
2011-03-23 |
2019-05-21 |
Фред Хатчинсон Кэнсер Рисерч Сентер |
Способ и композиции для клеточной иммунотерапии
|
|
PH12013502043A1
(en)
|
2011-04-01 |
2013-12-16 |
Memorial Sloan Kettering Cancer Center |
T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
|
|
ES2872077T3
(es)
|
2011-04-08 |
2021-11-02 |
Us Health |
Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
|
|
NZ616405A
(en)
|
2011-04-08 |
2015-11-27 |
Baylor College Medicine |
Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
|
|
US20130071414A1
(en)
|
2011-04-27 |
2013-03-21 |
Gianpietro Dotti |
Engineered cd19-specific t lymphocytes that coexpress il-15 and an inducible caspase-9 based suicide gene for the treatment of b-cell malignancies
|
|
CA2842798C
(en)
|
2011-07-25 |
2021-02-23 |
Nationwide Children's Hospital, Inc. |
Recombinant virus products and methods for inhibition of expression of dux4
|
|
CA2842368A1
(en)
|
2011-07-29 |
2013-02-07 |
The Trustees Of The University Of Pennsylvania |
Switch costimulatory receptors
|
|
WO2013021628A1
(ja)
|
2011-08-08 |
2013-02-14 |
パナソニック株式会社 |
半導体装置
|
|
WO2013033626A2
(en)
|
2011-08-31 |
2013-03-07 |
Trustees Of Dartmouth College |
Nkp30 receptor targeted therapeutics
|
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
|
ES2716298T3
(es)
|
2011-09-16 |
2019-06-11 |
Baylor College Medicine |
El microentorno tumoral como diana mediante el uso de células NKT manipuladas
|
|
CA2848410A1
(en)
|
2011-09-16 |
2013-03-21 |
The Trustees Of The University Of Pennsylvania |
Rna engineered t cells for the treatment of cancer
|
|
CA2851795C
(en)
*
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-cd22 chimeric antigen receptors
|
|
HUE044633T2
(hu)
|
2011-10-27 |
2019-11-28 |
Genmab As |
Heterodimer fehérjék elõállítása
|
|
US20130131139A1
(en)
|
2011-11-17 |
2013-05-23 |
Oregon Health & Science University |
Ror1 as a gene target in acute lymphoblastic leukemia
|
|
EP2814846B1
(en)
|
2012-02-13 |
2020-01-08 |
Seattle Children's Hospital d/b/a Seattle Children's Research Institute |
Bispecific chimeric antigen receptors and therapeutic uses thereof
|
|
AU2013222284A1
(en)
|
2012-02-22 |
2014-08-07 |
The Trustees Of The University Of Pennsylvania |
Use of the CD2 signaling domain in second-generation chimeric antigen receptors
|
|
AU2013222288A1
(en)
|
2012-02-22 |
2014-08-14 |
The Trustees Of The University Of Pennsylvania |
Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
|
|
MX2014010183A
(es)
|
2012-02-22 |
2015-03-20 |
Univ Pennsylvania |
Composiciones y metodos para generar una poblacion persistente de celulas t utiles para el tratamiento de cancer.
|
|
EP2826963B1
(en)
|
2012-03-16 |
2021-01-13 |
Nittan Valve Co., Ltd. |
Mechanical lash adjuster
|
|
CN103483452B
(zh)
|
2012-06-12 |
2021-08-13 |
上海细胞治疗集团有限公司 |
双信号独立的嵌合抗原受体及其用途
|
|
CN112375846A
(zh)
|
2012-07-13 |
2021-02-19 |
宾夕法尼亚大学董事会 |
评估用于施用的转导t细胞的适用性的方法
|
|
AU2013289984B2
(en)
|
2012-07-13 |
2018-03-08 |
The Trustees Of The University Of Pennsylvania |
Use of CART19 to deplete normal B cells to induce tolerance
|
|
HRP20250822T1
(hr)
|
2012-07-13 |
2025-09-26 |
The Trustees Of The University Of Pennsylvania |
UPRAVLJANJE TOKSIČNOŠĆU ZA PROTUTUMORSKO DJELOVANJE CAR-a
|
|
AU2013289970A1
(en)
|
2012-07-13 |
2015-01-22 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for regulating CAR T cells
|
|
SG11201408787PA
(en)
|
2012-07-13 |
2015-01-29 |
Univ Pennsylvania |
Enhancing activity of car t cells by co-introducing a bispecific antibody
|
|
WO2014011993A2
(en)
|
2012-07-13 |
2014-01-16 |
The Trustees Of The University Of Pennsylvania |
Epitope spreading associated with car t-cells
|
|
KR102264290B1
(ko)
|
2012-08-20 |
2021-06-10 |
프레드 헛친슨 켄서 리서치 센터 |
세포 면역요법을 위한 방법 및 조성물
|
|
US9937205B2
(en)
|
2012-09-04 |
2018-04-10 |
The Trustees Of The University Of Pennsylvania |
Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
|
|
AR092745A1
(es)
|
2012-10-01 |
2015-04-29 |
Univ Pennsylvania |
Composiciones que comprenden un dominio de union anti-fap y metodos para hacer blanco en celulas estromales para el tratamiento del cancer
|
|
CN112458057A
(zh)
|
2012-10-02 |
2021-03-09 |
纪念斯隆-凯特琳癌症中心 |
用于免疫疗法的组合物和方法
|
|
WO2014055657A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Use of a trans-signaling approach in chimeric antigen receptors
|
|
JP6338252B2
(ja)
|
2012-10-24 |
2018-06-06 |
アメリカ合衆国 |
Ｍ９７１キメラ抗原受容体
|
|
NZ711807A
(en)
|
2013-02-06 |
2020-06-26 |
Celgene Corp |
Modified t lymphocytes having improved specificity
|
|
PT3613439T
(pt)
|
2013-02-15 |
2021-05-12 |
Univ California |
Recetor de antigénio quimérico e métodos de utilização do mesmo
|
|
PL2958943T3
(pl)
|
2013-02-20 |
2020-04-30 |
The Trustees Of The University Of Pennsylvania |
Leczenie nowotworu złośliwego za pomocą humanizowanego chimerycznego receptora antygenowego anty-egfrviii
|
|
ES2814962T3
(es)
*
|
2013-02-20 |
2021-03-29 |
Novartis Ag |
Fijación eficaz como objetivo de la leucemia humana primaria utilizando células T modificadas con receptor de antígeno quimérico anti-CD123
|
|
EP2964753B1
(en)
|
2013-03-07 |
2018-04-25 |
Baylor College of Medicine |
Targeting cd138 in cancer
|
|
US9434935B2
(en)
|
2013-03-10 |
2016-09-06 |
Bellicum Pharmaceuticals, Inc. |
Modified caspase polypeptides and uses thereof
|
|
AU2014241843B2
(en)
|
2013-03-14 |
2019-05-02 |
Icahn School Of Medicine At Mount Sinai |
Newcastle disease viruses and uses thereof
|
|
AU2014236726A1
(en)
|
2013-03-14 |
2015-09-17 |
Bellicum Pharmaceuticals, Inc. |
Methods for controlling T cell proliferation
|
|
ES3058841T3
(en)
|
2013-03-15 |
2026-03-13 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
TWI654206B
(zh)
|
2013-03-16 |
2019-03-21 |
諾華公司 |
使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
|
|
WO2014190273A1
(en)
|
2013-05-24 |
2014-11-27 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptor-targeting monoclonal antibodies
|
|
JP6467406B2
(ja)
|
2013-06-05 |
2019-02-13 |
ベリカム ファーマシューティカルズ， インコーポレイテッド |
カスパーゼポリペプチドを使用して部分的なアポトーシスを誘導するための方法
|
|
EP3057991B8
(en)
|
2013-10-15 |
2019-09-04 |
The Scripps Research Institute |
Chimeric antigen receptor t cell switches and uses thereof
|
|
SG11201603484PA
(en)
*
|
2013-11-21 |
2016-05-30 |
Ucl Business Plc |
Cell
|
|
US9512084B2
(en)
|
2013-11-29 |
2016-12-06 |
Novartis Ag |
Amino pyrimidine derivatives
|
|
KR102225489B1
(ko)
|
2013-12-17 |
2021-03-10 |
제넨테크, 인크. |
항-cd3 항체 및 이의 사용 방법
|
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
|
EP3808410A1
(en)
|
2013-12-20 |
2021-04-21 |
Cellectis |
Method of engineering multi-input signal sensitive t cell for immunotherapy
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
|
JP2017513818A
(ja)
|
2014-03-15 |
2017-06-01 |
ノバルティス アーゲー |
キメラ抗原受容体を使用する癌の処置
|
|
EP3119425B1
(en)
|
2014-03-15 |
2020-09-23 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
EP4066834A1
(en)
|
2014-03-19 |
2022-10-05 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
|
|
SI3888674T1
(sl)
|
2014-04-07 |
2024-08-30 |
Novartis Ag |
Zdravljenje raka z uporabo antigenskega himernega receptorja proti-CD19
|
|
CN112877291A
(zh)
*
|
2014-04-10 |
2021-06-01 |
西雅图儿童医院 (Dba西雅图儿童研究所) |
基因修饰的t细胞产品、其制备方法和用途
|
|
EP3137498A1
(en)
|
2014-05-02 |
2017-03-08 |
Cellectis |
Cs1 specific multi-chain chimeric antigen receptor
|
|
US20170274014A1
(en)
|
2014-07-21 |
2017-09-28 |
Jennifer Brogdon |
Combinations of low, immune enhancing, doses of mtor inhibitors and cars
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
EP3193915A1
(en)
|
2014-07-21 |
2017-07-26 |
Novartis AG |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
|
JP6736540B2
(ja)
|
2014-07-21 |
2020-08-05 |
ノバルティス アーゲー |
Ｃｌｌ−１キメラ抗原受容体を使用した癌の処置
|
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
|
US20170226495A1
(en)
|
2014-07-21 |
2017-08-10 |
Novartis Ag |
Sortase molecules and uses thereof
|
|
SG10201913765YA
(en)
|
2014-07-21 |
2020-03-30 |
Novartis Ag |
Treatment of cancer using a cd33 chimeric antigen receptor
|
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
|
AU2015301460B2
(en)
|
2014-08-14 |
2021-04-08 |
Novartis Ag |
Treatment of cancer using GFR alpha-4 chimeric antigen receptor
|
|
RU2020117196A
(ru)
|
2014-08-19 |
2020-10-15 |
Новартис Аг |
Химерный антигенный рецептор (car) против cd123 для использования в лечении злокачественных опухолей
|
|
JP6839074B2
(ja)
|
2014-09-17 |
2021-03-03 |
ノバルティス アーゲー |
養子免疫療法のためのキメラ受容体での細胞毒性細胞のターゲティング
|
|
CA2963935A1
(en)
|
2014-10-08 |
2016-04-14 |
Novartis Ag |
Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
|
|
WO2016061368A1
(en)
|
2014-10-15 |
2016-04-21 |
The Children's Hospital Of Philadelphia |
Compositions and methods for treating b-lymphoid malignancies
|
|
WO2016100232A1
(en)
|
2014-12-15 |
2016-06-23 |
The Regents Of The University Of California |
Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20
|
|
PT3560953T
(pt)
|
2014-12-24 |
2024-03-26 |
Autolus Ltd |
Célula
|
|
IL253149B2
(en)
|
2014-12-29 |
2023-11-01 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2016115482A1
(en)
|
2015-01-16 |
2016-07-21 |
Novartis Pharma Ag |
Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptor
|
|
US11161907B2
(en)
*
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
|
WO2016149578A1
(en)
*
|
2015-03-19 |
2016-09-22 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Dual specific anti-cd22-anti-cd19 chimeric antigen receptors
|
|
EP3280795B1
(en)
|
2015-04-07 |
2021-03-24 |
Novartis AG |
Combination of chimeric antigen receptor therapy and amino pyrimidine derivatives
|
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
|
GB201507111D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
JP6961497B2
(ja)
|
2015-06-25 |
2021-11-05 |
アイセル・ジーン・セラピューティクス・エルエルシー |
キメラ抗体受容体（ＣＡＲｓ）の構成およびその使用方法
|
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
|
US11667691B2
(en)
|
2015-08-07 |
2023-06-06 |
Novartis Ag |
Treatment of cancer using chimeric CD3 receptor proteins
|
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
|
MX2018003353A
(es)
|
2015-09-17 |
2018-09-17 |
Novartis Ag |
Terapias con celulas cart con una eficacia mejorada.
|
|
US11413340B2
(en)
|
2015-12-22 |
2022-08-16 |
Novartis Ag |
Mesothelin chimeric antigen receptor (CAR) and antibody against PD-L1 inhibitor for combined use in anticancer therapy
|
|
AU2016380262B2
(en)
|
2015-12-28 |
2023-02-09 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
|
CN109072195A
(zh)
|
2015-12-30 |
2018-12-21 |
诺华股份有限公司 |
具有增强功效的免疫效应细胞疗法
|
|
WO2017149515A1
(en)
|
2016-03-04 |
2017-09-08 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11549099B2
(en)
|
2016-03-23 |
2023-01-10 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
|
CN105949317B
(zh)
|
2016-04-12 |
2019-07-02 |
上海优卡迪生物医药科技有限公司 |
抗cd20嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
|
|
CN109715808A
(zh)
|
2016-04-15 |
2019-05-03 |
诺华股份有限公司 |
用于选择性蛋白质表达的组合物和方法
|
|
EP3464375A2
(en)
|
2016-06-02 |
2019-04-10 |
Novartis AG |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
|
US20190336504A1
(en)
|
2016-07-15 |
2019-11-07 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
|
KR20230100748A
(ko)
|
2016-07-28 |
2023-07-05 |
노파르티스 아게 |
키메라 항원 수용체 및 pd-1 억제제의 조합 요법
|
|
CN110267677A
(zh)
|
2016-08-01 |
2019-09-20 |
诺华股份有限公司 |
使用与原m2巨噬细胞分子抑制剂组合的嵌合抗原受体治疗癌症
|
|
EP3523290A4
(en)
|
2016-09-30 |
2020-07-29 |
Novartis AG |
IMPROVED EFFICIENCY IMMUNE EFFICIENT CELL THERAPIES
|
|
MY200337A
(en)
|
2016-10-07 |
2023-12-20 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a cd20 binding domain
|
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
US20200048359A1
(en)
|
2017-02-28 |
2020-02-13 |
Novartis Ag |
Shp inhibitor compositions and uses for chimeric antigen receptor therapy
|
|
SG11201908719QA
(en)
|
2017-03-22 |
2019-10-30 |
Novartis Ag |
Biomarkers and car t cell therapies with enhanced efficacy
|
|
CA3054621A1
(en)
|
2017-03-22 |
2018-09-27 |
Novartis Ag |
Compositions and methods for immunooncology
|
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
JP7656401B2
(ja)
|
2017-05-15 |
2025-04-03 |
アメリカ合衆国 |
バイシストロン性キメラ抗原受容体及びそれらの使用
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
RU2020116579A
(ru)
|
2017-10-25 |
2021-11-25 |
Новартис Аг |
Способы получения клеток, экспрессирующих химерный антигенный рецептор
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
US20200061113A1
(en)
|
2018-04-12 |
2020-02-27 |
Novartis Ag |
Chimeric antigen receptor therapy characterization assays and uses thereof
|
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
|
US20200085869A1
(en)
|
2018-05-16 |
2020-03-19 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor therapies
|
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
EP3844267B1
(en)
|
2018-08-31 |
2025-06-25 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
WO2020069405A1
(en)
|
2018-09-28 |
2020-04-02 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Chimeric antigen receptors cd19 and cd22 and their uses
|
|
EP4104187A1
(en)
|
2020-02-14 |
2022-12-21 |
Novartis AG |
Method of predicting response to chimeric antigen receptor therapy
|
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
MX2023005609A
(es)
|
2020-11-13 |
2023-05-29 |
Novartis Ag |
Terapias de combinacion con celulas que expresan receptores quimericos para el antigeno (car).
|